Comparison of clinical effects of capecitabine combined with oxaliplatin or irinotecan in the treatment of colorectal cancer with liver metastasis

Abstract

Objective To compare the clinical effect of capecitabine combined with oxaliplatin or irinotecan in the treatment of colorectal cancer with liver metastasis. Methods From January 2016 to January 2018, 100 patients with colorectal cancer complicated with liver metastasis admitted in Jinhua Central Hospital were selected and randomly divided into control group and observation group according to the random number table method, with 50cases in each group. Both two groups were given 1 000mg/m2 capecitabine twice a day treatment for 2 consecutive weeks. In addition, the control group was treated with 130mg/m2 oxaliplatin, while the observation group was treated with 150mg/m2 irinotecan. The adverse reactions, short-term efficacy, median survival time and progression survival time were observed and compared between the two groups. Results The objective remission rate of patients in the observation group was 48.00%, which was significantly higher than 36.00% in the control group (χ2=7.253, P 0.05), including anemia, thrombocytopenia, leukopenia, stomatitis, hemorrhage, peripheral neuropathy, liver injury, hand-foot syndrome, nausea and vomiting, and alopecia. Conclusion For patients with colorectal cancer with liver metastasis, capecitabine combined with irinotecan can effectively improve the clinical efficacy of patients, greatly improve the patients' tolerance, but also can reduce the incidence rates of adverse reactions in patients .Its effect is better than capecitabine combined with oxaliplatin, and is worthy of popularizing in clinic. Key words: Colorectal neoplasms; Survival time; Side effects; Irinotecan; Capecitabine; Oxaliplatin